Dolutegravir

An HIV integrase inhibitor, FDA-approved with other antiretrovirals for HIV-1 infection, and with rilpivirine as a complete regimen in virologically suppressed adults.

psilodex.org/m/dolutegravir · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~14 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Dolutegravir”, v2026.10.05. psilodex.org/m/dolutegravir

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

HIV-1 infection (with other antiretrovirals; adults and children weighing at least 2 kg)
HIV-1 infection with rilpivirine as a complete regimen (virologically suppressed adults)

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; no linking mechanism is described. Separately, its label reports suicidal thoughts, mainly in people with past depression or other psychiatric illness.

Detail Not studied with psilocybin, and no mechanism linking them has been described. The body clears dolutegravir mainly through UGT1A1, with some CYP3A. Separately, its label reports suicidal ideation, attempt, behavior or completion. These occurred mainly in people with a pre-existing history of depression or other psychiatric illness. Sources [1]

Human data with psilocybin: No psilocybin data; based on its label
Half-life: ~14 h (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Liver injury: The label or source warns of liver injury, from raised liver enzymes to liver failure. Liver disease also affects how the body clears psilocin. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

TIVICAY and TIVICAY PD (dolutegravir) - ViiV · FDA label (DailyMed) — revised 2026-10 | Liver injury: 5.2 Hepatotoxicity | "Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A." 6 "Psychiatric Disorders: Suicidal ideation, attempt, behavior, or completion. These events were observed primarily in participants with a pre-existing history of depression or other psychiatric illness." | 12.3 "Dolutegravir has a terminal half-life of approximately 14 hours"
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →